SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature

被引:153
作者
Burke, Kelly R. [1 ]
Schumacher, Christine A. [1 ]
Harpe, Spencer E. [1 ]
机构
[1] Midwestern Univ, Chicago Coll Pharm, Dept Pharm Practice, Chicago, IL USA
来源
PHARMACOTHERAPY | 2017年 / 37卷 / 02期
关键词
adverse drug reactions; diabetes; Food and Drug Administration; ketoacidosis; sodium glucose cotransporter-2 inhibitors; COTRANSPORTER; 2; INHIBITOR; CANAGLIFLOZIN; OUTCOMES; PATIENT; SAFETY;
D O I
10.1002/phar.1881
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study ObjectiveCurrently only minimal information is available regarding risk factors for the development of sodium glucose cotransporter-2 inhibitor (SGLT2i)-related diabetic ketoacidosis (DKA). We aim to identify individual patient characteristics associated with cases of SGLT2i-related DKA to better describe potential risk factors. DesignSystematic review of primary literature. PatientsThirty-four case reports of patients with type 1 and type 2 diabetes mellitus who developed DKA while receiving an SGLT2i. Methods and Main ResultsThis systematic review investigated the relationship between SGLT2i and DKA in patients with diabetes. The existing literature was reviewed with a primary outcome to identify patient-specific factors contributing to the incidence of ketoacidosis in patients with diabetes who were treated with a SGLT2i. Numerous databases were searched to identify appropriate primary literature. Search terms included canagliflozin, dapagliflozin, empagliflozin, SGLT2, sodium glucose cotransporter-2 inhibitor, diabetic ketoacidosis, ketoacidosis, metabolic acidosis, and acidosis. Primary literature was analyzed via descriptive statistics. Thirty-four individual case reports were identified via the primary literature search. Two-thirds (25 cases) involved patients with a diagnosis of type 2 diabetes mellitus (T2DM). The average blood glucose on presentation for SGLT2i-induced DKA was 265.6140.7mg/dl (14.7 +/- 7.8mmol/L), with common symptoms including nausea, vomiting, and abdominal pain. Common precipitating factors included patients who were diagnosed with T2DM and were subsequently found to have latent autoimmune diabetes of adulthood, patients who had recently undergone major surgery, or patients who had decreased or discontinued insulin. No cases were fatal. ConclusionIn this review, episodes of DKA with SGLT2i use were characterized by lower blood glucose levels and were often caused by a precipitating factor. Understanding precipitating factors for SGLT2i-related DKA may help providers better identify patients at risk for development of DKA.
引用
收藏
页码:187 / 194
页数:8
相关论文
共 33 条
[1]  
[Anonymous], 2019, DIABETES CARE, V42, pS1, DOI [10.2337/dc20-Sint, 10.2337/dc19-Sint01, 10.2337/dc19-SINT01, 10.2337/dc20-SINT, 10.2337/dc16-S001]
[2]  
[Anonymous], 2015, DRUG SAF COMM FDA WA
[3]  
[Anonymous], 2015, FDA DRUG SAF COMM FD
[4]  
Bell David S H, 2004, Am J Ther, V11, P308, DOI 10.1097/01.mjt.0000102372.28723.2b
[5]  
Bonanni Fernando B, 2016, Surg Obes Relat Dis, V12, pe11, DOI 10.1016/j.soard.2015.08.502
[6]  
Burr K, 2015, ENDO 2015 MARCH 7 SA
[7]  
Campbell RK, 2010, AM J HEALTH-SYST PH, V26, P589
[8]  
Chaudry F, 2015, AACE 2015 MAY 15 NAS
[9]   The stress response to trauma and surgery [J].
Desborough, JP .
BRITISH JOURNAL OF ANAESTHESIA, 2000, 85 (01) :109-117
[10]   Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program [J].
Erondu, Ngozi ;
Desai, Mehul ;
Ways, Kirk ;
Meininger, Gary .
DIABETES CARE, 2015, 38 (09) :1680-1686